3SOF

 Simulations Plus Reports Third Quarter FY2007 Financial Results
Tuesday , July 03, 2007 09:15ET

LANCASTER, Calif., Jul 03, 2007 (BUSINESS WIRE) -- Simulations Plus, Inc. (AMEX:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for the third quarter of its 2007 fiscal year (3Q07) ended May 31, 2007.

Ms. Momoko Beran, chief financial officer of Simulations Plus, stated: "This quarterly report has come together more quickly than is customary. Part of the reason is that some information we need is now available more quickly in electronic format, while another part is that due to my travel schedule and also the schedule of our auditors, extra effort was made to complete certain tasks early. The result is that we were able to complete the 10Q much faster than normal. I hope future 10Q's will be released earlier than they were in the past, but I cannot guarantee it. Our next report will be our annual report, which requires considerably more preparation than the quarterly reports, so I don't think it will be released much earlier than it has been in the past."

Ms Beran continued: "I'm very pleased to report that consolidated revenues for 3Q07 set a new record for any quarter at $2,631,000, an increase of 47.1% from $1,788,000 in the third quarter of fiscal year 2006 (3Q06). The previous record for any quarter was last quarter (2Q07). Revenues in that quarter were $2,534,000, which included large pharmaceutical software licenses from two customers that accounted for about $1 million in revenues. In contrast, 3Q07 did not include any such large orders. Revenues from pharmaceutical software and services were up 51.3% to $1,659,000 from $1,097,000 in 3Q06. Revenues for our Words+ subsidiary also set a new record for any quarter at $972,000, an increase of 40.6% from $692,000 in 3Q06. Consolidated gross profit increased 53.6% to $2,080,000 in 3Q07 from $1,355,000 in 3Q06. R&D expense increased 91.0% to $227,000 in 3Q07 from $119,000 in 3Q06, primarily due to expansions within our Life Sciences staff. Consolidated SG&A increased 11.3% to $885,000 in 3Q07, compared to $796,000 in 3Q06; however, as a percentage of sales, SG&A decreased from 44.5% to 33.6%. Major expense increases were selling expenses, such as commissions to dealers and trade shows, investor relations, accrued bonus to officers, salaries, and payroll-related expenses such as health insurance and payroll taxes, which outweighed decreases in equipment rental and professional fees.

"Net income before taxes for 3Q07 more than doubled, with an increase of 118% to $1,003,000 from $460,000 in 3Q06. Third quarter earnings were impacted by a provision for income taxes of $221,000 that will not actually be paid, but rather will be a write-off from our deferred tax asset. Consolidated net earnings for the quarter also more than doubled with an increase of 103% over last year's third quarter to $782,000, or $0.09 per diluted share based on 9,180,629 shares, as compared to $386,000, or $0.05 per diluted share for 3Q06, based on 8,226,066 split-adjusted shares. Thus, earnings per share increased by 80%, even with the increase in number of fully diluted shares of almost 12%. Cash at the end of the third quarter was $3,038,000, with accounts receivable of almost another $3 million. Current assets were about $6.5 million, and current liabilities were less than $0.9 million, for a very healthy current ratio of about 7.3."

Ms. Beran continued: "For the first nine months of FY2007, consolidated revenues set a new nine-month record at $6,622,000, an increase of $2,533,000 or 61.9% from $4,089,000 in the first nine months of FY2006. These nine-month revenues exceed any previous entire fiscal year. Revenues from pharmaceutical software and services were nearly doubled, up 96.9% to $4,291,000 from $2,179,000 in the first nine months of FY2006. Revenues for our Words+ subsidiary increased 22.0% in the first nine months, to $2,330,000 from $1,910,000. In the first nine months, consolidated gross profit increased over $2 million, or 72.7% to $5,072,000 from $2,937,000; R&D expense increased 86.7% to $627,000 from $336,000, primarily due to expansions within our Life Sciences staff, and SG&A increased 22.1% to $2,578,000, compared to $2,112,000; however, as a percentage of sales, SG&A decreased from 51.7% to 38.9%. Major expense increases were for the same reasons described above for the third quarter.

"Net income before taxes for the first nine months of FY2007 more than tripled, with an increase of 276% to $1,953,000 from $519,000. The first nine months' earnings were impacted by a provision for income taxes of $430,000 that will not actually be paid, but rather will be a write-off from our deferred tax asset. Consolidated net earnings also more than tripled, with an increase of 249% to $1,523,000, or $0.17 per diluted share based on 8,893,882 shares, as compared to $436,000, or $0.05, based on 8,104,960 split-adjusted shares in the first nine months of FY2006. Shareholders' equity at the end of the first nine months was $7,682,000, an increase of 36% in the first nine months from $5,669,000 at the beginning of the fiscal year."

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: "When we reported the record second quarter, I wondered if we'd be able to beat it in the third quarter, knowing that we would not have the benefit of the two large orders that came in during the second quarter. I'm happy to report that not only did we beat it, but after three quarters, revenues are already almost a million dollars more than all of last fiscal year. Our cash position remains excellent and we continue to be debt-free. We're actively seeking acquisition opportunities; however, there can be no assurances that we'll proceed with any of them. We have received our first SBIR grant in the life sciences, and we have another proposal in review now."
Woltosz continued: "Simulations Plus is strong and getting stronger. We are experiencing continued growing demand for our products and services, and we continue to enjoy an outstanding reputation for high quality and attention to customers' needs. Our trailing twelve months revenues are now $8.4 million, and trailing twelve months earnings are over $0.19 per share. We expect to provide updated revenue guidance in our conference call, which will be on Thursday, July 5, 15 minutes after the market closes."

Q3 is excellent.

I think that nobody anticipated Q3 to be so strong!  This means that
the products are gaining traction on the market. Q4 is expected to be
even stronger.

This company is way ahead of its own expectation and its stock price
is down from its top in April (healthy correction).  As this company
is stronger than it was in April, I expect this stock to challenge
again its previous top. Today we're at $11.89, so we have a nice run
up until $16!

To state it differently, this stock has anything but good news, a low
float (3.64m), no debt, good cash flow, increasing revenues and net
income and a cheap price!  As there has been a recent market
correction due to the past growth, there is no risk of further down
side.

The analyst covering this stock will have to upgrade his rating of the firm in the next days.

awesome, upgrade is coming soon 

link for more details:
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5038006

chart:

This company is undervalued at current prices.

Something has changed in SLP. For the second consecutive quarter this
company is making more money in one quarter than in an entire fiscal
year!

For example,
2005 net income for the full year: 0.26 million.
2006 net income for the full year: 0.68 million.

In Q3, SLP made 0,78 million. That's 3 times more than for the full
year 2005 and 15% more than the full year 2006. In only one quarter!

The best is still to come as sales will continue to grow, may be even
stronger than before.

That's why I think that the current prices barely reflects the
company's current value (it is therefore undervalued) and by no mean
reflects its future value.

It is probably a very good time to accumulate at these low prices
before the analyst update SLP's valuation and the price go up again.


You could ask me: so why is the stock down? It is down because 3
months ago the stock price was too high. At that time, nobody believed
that Q3 could match Q2'results as Q2 incorporated several major deals.
Hence the drop. However, the unthinkable happened. Without any major
deal, Q3 beat Q2. This means that something on the business side has
changed. The consequence is that, at current prices, SLP becomes
undervalued again.

Had SLP missed Q3 entirely, shorting might have been correct. Shorting
this stock now is silly.

It is clear that now the upward potential is far greater than the
downward potential.

Q3 CONFERENCE CALL QUOTES


The CEO start by reviewing the different programs and gives an update on them.

ADMET Predictor:

"Revenues for ADMET Predictor has been growing nicely"

"ADMET Predictor is the most accurate on market"

Expanding the product to predict a standard test required by the FDA

The 100k grant is only the first step. The total amount could be up 750k in the future. CEO says that there is a "high probability" that SLP can get it. The money SLP get for free is some money they don't have to take out of earnings.

"the quality speaks for itself"

"rated number one in accuracy"



ClassPharmer:
training 15 new users in Japan. "you could see the interest and excitement"
"the new capabilities are very exciting"
"we expect Class Farmer to continue to grow in terms revenues and earnings"


DDDPlus
"ACCEPTANCE IS ACCELERATING NICELY"

"other development activities that I won't discuss right away for COMPETITIVE REASONS"



GastroPlus:
"industry GOLD STANDARD"
"by far the industry's most advanced and wildly used simulation of oral absorption"
"very very satisfying"

"3 out of our 4 programs will have MAJOR NEW RELEASES IN THE COMING WEEKS"



about consulting contracts:
"consulting contracts continue to be a growing part of the business"

"GETTING UNSOLICITED CALLS FROM NEW CUSTOMERS ON A FREQUENT BASIS"

"it is becoming a significant contributor to revenues and earnings"

"there are other ways to give a dose but again I won't discuss right away for COMPETITIVE REASONS"

"the contact is allowing us the expand the capability of the program and provide a valuable service to the customer at the same time"

"and this type of contracts LEADS TO ADDITIONAL SOFTWARE LICENSES"

"allows to build relationships not only with the scientists but also with management"



"we're really enjoying a nice time in our history right now, I SEE NOTHING BUT A VERY NICE FUTURE GOING FORWARD"

"we're getting more aggressive with our marketing and sales .. RESULTS ARE VERY NICE"


Talking about Q3:
"MORE THAN DOUBLE NET EARNING FOR THE QUARTER"

"SALES UP 70%"

"there is an AWFUL LOT OF NEW BUSINESS"
"accumulation of smaller order that gives us that tremendous increase over last year third quarter"


"in the first nine month WE'RE ALREADY EXCEEDED LAST FISCAL YEAR and we have still one full quarter to go. It is very satisfying"


Strategic considerations:
good results from marketing and sales
our cash position continues to improve

acquisition: "we have ACTIVE DISCUSSIONS UNDER WAY FOR POTENTIAL ACQUISITIONS"


"WordPlus had a record quarter, We're very happy to see that"

"We don't want that cash just sitting there, WE'RE GOING TO PUT IT TO WORK"


"we believe this is an EMERGING HIGH GROWTH MARKET"

"pharmaceutical industry ADOPTION OF SIMULATION AND MODELING IS ACCELERATING"

"the growth has been tremendous, now a 0.17 EPS for 3 quarters. Analyst predicted 0.18EPS for the year"

debt free, strong cash position, world class scientific team


--- questions
revenue guidance "still early in fourth quarter and as most people know who's followed this for a while many sales seems to happen in the last couple of weeks"

"we're going to be a VERY CONSERVATIVE we're going to predict at least 2.9 million over last year in revenues. We feel that's a SAFE PREDICTION".
"I wouldn't give a number that I feel I could not beat."

My take on this: he should give a guidance that is not accurate. Some bashers on the yahoo board are using this to make it look like SLP has no future. This is highly dishonest and far from what has been said in the conference call.


Question about contract services:
how many contract this year compared to last year and for next year?
Answer: "momentum is continuing, we're getting unsolicited calls"
"2 or 3 contracts on-going constantly now"
Some contracts are short (a few weeks) and SLP makes 30k  on them.  Some contracts are much larger and take many month: 6 figures contracts (several 100k, no specific numbers).


"attracting some very talented people"



CC conclusion:

"I'm optimistic because I see that THE PHARMACEUTICAL INDUSTRY IS TURNING TO SIMULATION AND MODELING MORE AND MORE AS A STANDARD PART OF RESEARCH."

"I think that managers have realized that PRODUCTIVITY OF THESE TOOLS IS SO HIGH THAT THE COSTS OF THE TOOLS IS ACTUALLY MORE THAN PAID for by savings of time and costs in other areas."

Simulations Plus to Present at Atlantic City Global Equities Investor Conference July 17
Friday , July 13, 2007 09:15ET

LANCASTER, Calif., Jul 13, 2007 (BUSINESS WIRE) -- Simulations Plus, Inc. (AMEX:SLP), a leading provider of ADMET absorption simulation and structure-to-property prediction software for pharmaceutical discovery and development, announced today that Walt Woltosz, the company's chairman and chief executive officer, will present at the Summer Global Equities Conference organized by Friedland Investment Events to be held at Bally's in Atlantic City, New Jersey, on July 15-17, 2007. The Simulations Plus presentation will be on July 17.

Presentation slides:
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5051842

&
TB upgade
Key Investment Considerations:
We are upgrading our rating on shares of Simulations Plus, Inc. (AMEX: SLP) to Speculative Buy from Neutral, primarily due to excellent fiscal third quarter 2007 results, as well as expected positive growth trends over the next twelve months. We are setting a twelve-month price target of $12.75 per share based on our sales, EBITDA, and earnings per share forecasts for fiscal 2008.
On July 3, 2007, the Company announced that third quarter fiscal 2007 net sales increased by 47.1% to $2.631 million versus $1.788 million in the same period last year. Top line growth was led by pharmaceutical software sales, which increased on a year-over-year basis by 51.3%. Net income increased to $0.782 million or $0.09 per diluted share versus $0.386 million or $0.05 per diluted share in the third quarter of fiscal 2006.
Based on results for the first nine months of fiscal 2007 and Management's public guidance, we are adjusting our net sales and net income forecasts to $8.891 million and $2.041 million or $0.23 per diluted share, respectively. Our prior forecasts called for net sales and net income of $8.505 million and $1.844 million or $0.21 per diluted share, respectively.
We are adjusting our estimates for fiscal 2008. Given current licensing trends, renewals, and potential for new customers, our revised net sales and net income forecasts are $11.100 million and $2.790 million or $0.30 per diluted share. Our prior forecasts called for net sales and net income of $10.545 million and $2.750 million or $0.30 per diluted share.

Report:
http://www.taglichbrothers.com/equityuniverse/companies/simplus/simplus-07162007.pdf

SLP update:
1)
Simulations Plus Releases ADMET Predictor(TM) Version 2.3
Tuesday , July 24, 2007 09:15ET

LANCASTER, Calif., Jul 24, 2007 (BUSINESS WIRE) -- Simulations Plus, Inc. (AMEX:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that it has released the next major upgrade to its industry leading ADMET Predictor software.

Dr. Robert Fraczkiewicz, team leader for ADMET Cheminformatics, said: "This new release, called version 2.3, adds both more accurate predictive models as well as a list of new features that have been inspired by user feedback and our own internal use of the program. ADMET Predictor already enjoyed best-in-class status by achieving number one ranking in every published comparison study for software that predicts properties of molecules from just their structure. In version 2.3, we have retrained all models with an enhanced set of molecular descriptors, resulting in even more accuracy in our predictions."

Ron Creeley, vice president of marketing and sales for Simulations Plus, added: "Sales of ADMET Predictor have been growing steadily over the past few years. We believe the integration of ADMET Modeler(TM) into ADMET Predictor last year as a single package and our unique position as number one in each of the independent comparison studies have been major contributors to increased interest in the program."

2)

Simulations Plus Releases Unique DNA Mutation Predictor
Thursday , July 26, 2007 09:15ET

LANCASTER, Calif., Jul 26, 2007 (BUSINESS WIRE) -- Simulations Plus, Inc. (AMEX:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that it has released a unique new predictive capability as part of its new ADMET Predictor(TM) Version 2.3.

Dr. Michael Bolger, chief scientist for Simulations Plus, said: "One of the FDA-required tests for any new drug is for the potential to cause mutations in the DNA of various strains of salmonella. Salmonella is not just a single bacterial form; rather, there are thousands of different strains. In the past, we and others have built our predictive software models on data sets where the mutagenicity data were pooled for all strains. Simulations Plus' new predictive capability is not just one model, but a series of models based on data for ten different strains of salmonella. After months of work, we've developed a capability for predicting whether a particular new drug-like molecule is likely to cause mutations in any one of these strains. The overall predictive accuracy is improved with this approach over models built on pooled data for different strains."

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: "Our ability to create these new software models comes from a database we acquired as part of our Bioreason asset acquisition in November 2005. One of the many assets we acquired was a proprietary database of over 5,000 compounds with specific data for mutagenicity for ten different strains of salmonella that had been developed by scientists at Bioreason. We believe this mutagenicity database which we now own is unique, and that our new predictive capability is also unique, further enhancing our best-in-class structure-to-property prediction software, ADMET Predictor."

Chart (doubled bottom at 9$?):

chart update:

update:
U.S. FDA Expands Simulations Plus Software Licenses
Wednesday, August 29, 2007 09:15ET

LANCASTER, Calif., Aug 29, 2007 (BUSINESS WIRE) -- Simulations Plus, Inc. (AMEX:SLP), a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Food and Drug Administration for additional licenses for the Company's GastroPlus(TM) simulation software and new licenses for the Company's DDDPlus(TM) software as well. DDDPlus is the world's only in vitro dissolution software for the formulation scientist.

Ron Creeley, vice president of marketing and sales for Simulations Plus, said: "These software licenses are in addition to the GastroPlus license announced last January. We're excited that FDA scientists will have both GastroPlus and DDDPlus to assist in their simulation and modeling activities. GastroPlus continues to enjoy 'gold standard' status in the pharmaceutical industry, and DDDPlus remains the only software of its kind. Industry licenses for both products have increased nicely during this fiscal year."

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said:
"As we noted in January, the FDA's position in advocating for better simulation and modeling tools was expressed in its well-known white paper entitled, 'Innovation or Stagnation, Challenge and Opportunity on the Critical Path to New Medical Products' released in March 2004. In it, the FDA stated: '. . . a new product development toolkit - containing powerful new . . . methods such as . . . computer-based predictive models . . . is urgently needed. . . . The medical product development process is no longer able to keep pace with basic scientific innovation. Only a concerted effort to apply the new biomedical science to medical product development will succeed in modernizing the critical path.'"

SLP: Jumps +6.55%; Vol +129%; Last 90 Min of Trading
Wednesday, August 29, 2007 16:21ET

During the last 90 minutes of today's session, shares of Simulations Plus Inc (AMEX: SLP) demonstrated a strong UPWARD close relative to its 13:30 ET statistics. "Strong Closers" are determined by proprietary Knobias calculations performed during the last segment of each trading day.

sym: SLP       @13:30 ET        @CLOSE      % CHANGE
----------   -----------   -----------  ------------
PRICE             $11.90        $12.68        +6.55%
VOLUME            77,800       178,500      +129.43%
#TRADES              231           562      +143.29%
DAY-HI            $12.00        $12.68       LATE-HI
DAY-LO            $10.92        $10.92           N/A

TODAY'S RAiDAR HEADLINES for SLP:


08/29/2007 08:17 SLP: Receives Purchase Order from FDA for GastroPlus(TM) Simulation Software - knobias

2nd hit on 2nd day 

U.S. National Institutes of Health Licenses Simulations Plus' ClassPharmer(TM) Software
Thursday , August 30, 2007 09:15ET

LANCASTER, Calif., Aug 30, 2007 (BUSINESS WIRE) -- Simulations Plus, Inc. (AMEX:SLP), a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. National Institutes of Health (NIH) for its best-in-class ClassPharmer software product.

"It's been a busy final week of our fourth fiscal quarter. This license for the National Institutes of Health follows the announcement yesterday of the FDA licenses for GastroPlus(TM) and DDDPlus(TM), and it adds another important government agency to our list of customers," said Ron Creeley, vice president of marketing and sales for Simulations Plus. "We believe these agencies serve as trend-setting organizations and examples to companies who work in pharmaceutical research and development."

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: "We acquired ClassPharmer 3.5 and ChemTK(TM) almost two years ago, and merged them into the new ClassPharmer 4.X versions. The dramatic improvement in performance of the new version has caught the attention of chemists worldwide, and ClassPharmer is now a major contributor to our revenues and earnings. We have evolved its capabilities into molecule design as well, with the release earlier this year of the R-Table Exploder feature. Together with our ADMET Predictor(TM) software, the combination now enables chemists to evaluate molecules they have already synthesized, as well as to automatically generate new molecules and evaluate them for a variety of important properties. We believe our continuously evolving capability to design new molecules in conjunction with ADMET estimation is an effective formula for fueling the growth of Simulations Plus."

SLP: Volume Spike; 16% > 20-adsv, Stock +7.04%
Tuesday , September 04, 2007 11:25ET

This is the 4th VOLUME alert for SLP in the past 7 calendar days.

Trading for Simulations Plus Inc (AMEX: SLP) has been heavier than usual in today's session. By 11:25 ET, the stock had already traded 78,000 shares via 38 trades. The cumulative volume is 15.99% above its 20-day average of 67,250. Normally the stock experiences around 227 individual trades per session.

So far, today's volume surge has caused a net rise in SLP's stock price. At the time of this alert, the stock was trading at $14.290, up $0.940 (+7.04%).

One year ago, the Company's shares closed at $2.110. The price has gained more than 577 percent since then.

Over the last 10 trading session SLP has traded in a range between $9.500 and $14.420 and is currently trading 13.29% below its 52-week high of $16.480 set on April 10,2007 and 625.38% above its 52-week low of $1.970 from September 05,2006.

In the previous 3 sessions, SLP trading has displayed a mixed trend. Closing results have been as follows:

August 31, 2007 --- closed at $13.350 down $0.350 (-2.55%) on 175,500 shares
August 30, 2007 --- closed at $13.700 up $1.020 (+8.04%) on 294,700 shares
August 29, 2007 --- closed at $12.680 up $1.780 (+16.33%) on 178,500 shares

The Company last released news on August 30, 2007:

"U.S. National Institutes of Health Licenses Simulations Plus' ClassPharmer(TM) Software"

 
this will be a good day....
(of course I have sold much too early......  )

Simulations Plus Reports Fourth Quarter and Fiscal Year 2007 Preliminary Revenues
Thursday September 6, 9:15 am ET
Another New Record Set for Quarterly and Annual Revenues

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (AMEX:SLP - News), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported preliminary revenues for the fourth quarter and for the entire fiscal year 2007 (4Q07 and FY07) ended August 31, 2007.

Ms. Momoko Beran, chief financial officer of Simulations Plus, stated: "Because we expect that it will be late-November or so before we can file our 10-KSB, we want to provide what information we can now for our investors regarding our performance for the 4th quarter and the fiscal year. The complexities of tax accounting and other factors mean we will not know exact earnings until the 10-KSB and all audits are completed, but at least we can provide information regarding revenues at this time."

Ms. Beran continued: "I'm very pleased to report that consolidated revenues for 4Q07 set a new record for 4th quarters at $2,170,000, an increase of 22.8% from $1,767,000 in the fourth quarter of fiscal year 2006 (4Q06). The previous record fourth quarter was in FY03 when we booked a large three-year global pharmaceutical software license up-front. As we announced about two years ago, we no longer book multi-year licenses up-front, so this new record was achieved without the benefit of any such large order. Fourth quarter revenues from pharmaceutical software and services were up 38.5% to $1,395,000 from $1,007,000 in 4Q06. Revenues for our Words+ subsidiary were $775,000, an increase of 2.0% from $760,000 in 4Q06.

Ms. Beran continued: "For the entire fiscal year, revenues grew 50.2% to $8,792,000 from $5,855,000 in FY06, slightly exceeding our guidance of at least a $2.9 million increase in revenues over last fiscal year. Revenues from pharmaceutical software and services increased 78.5% to $5,686,000 in FY07 as compared to $3,186,000 in FY06. Revenues for our Words+ subsidiary increased 16.4% to $3,106,000 from $2,669,000 in FY06. The Company is financially strong, with over $4 million in cash at this time, and we remain debt-free."

Ron Creeley, vice president of marketing and sales for Simulations Plus, added: "As revenues grow year after year, it becomes more and more difficult to sustain a particular growth rate, much less to increase it, yet FY07 demonstrated sustained accelerated growth. This fiscal year, our customer base has grown from approximately 50 companies to approximately 80 companies. Increased orders from new departments within larger companies have also contributed to our growth, with almost every large pharmaceutical company increasing the number of licenses for Simulations Plus software, as well as a greater number of consulting contracts and our SBIR grant from the National Institutes of Health."

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: "It goes without saying that we're extremely pleased with our 50% revenue overall growth and 78% growth in pharmaceutical software and services revenues over last year. It is especially notable that this growth rate was achieved without the benefit of a single acquisition during the fiscal year. We had hoped to complete one or more before the end of the fiscal year, but that didn't happen. Nonetheless, our discussions are ongoing with such candidates for both the pharmaceutical and the disability sides of our business. This has been an exciting year in so many ways - strong sales, an ever-expanding world-class team that is innovative and dedicated, and an ever-growing list of outstanding collaborations with both government agencies and academia that we believe are crucial to our strategic growth initiatives."

 
Simulations Plus Announces Stock Dividend
Thursday September 13, 9:15 am ET
Board of Directors Approves Two-for-One Stock Split

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (AMEX:SLP - News), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that its Board of Directors has approved a two-for-one split of the Company's common stock. The total number of authorized shares remains at 20 million. Each shareholder of record at the close of business on the record date of Monday, September 24, 2007, will receive a stock dividend certificate of one additional share for every outstanding share held on the payment date of Monday, October 1, 2007, with fractional shares rounded up to the next whole share. Trading will begin on a split-adjusted basis on the ex-dividend date of October 2, 2007. In accordance with the terms of the Company's Stock Option Plans, employees with stock options will benefit from the split by receiving twice the number of shares at one-half the exercise price for options granted prior to the record date.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: "This dividend forward split will result in the total number of outstanding shares, including all possible options that may eventually be vested, of slightly over 19 million shares, with the public float increasing from about 4.16 million shares to about 8.3 million shares. We believe that increasing the number of shares in the public float is likely to increase liquidity and narrow the typical trading range for our stock, although there can be no assurances that either of these will happen. The board of directors has decided that a stock dividend is appropriate at this time because of our demonstrated sustained growth and our expectation that this will continue."